AIImpactLab
9 impact clustersWork & marketsCognition & learningTechnical failuresPrivacySecurityEnvironmentLaw & informationSocial good & healthSystemic risk
Search the evidence

Find the signal.

Search titles, impact clusters, countries, organizations and the full text of every analysis.

19 stories found

A transparent lung scan and clinical evidence panel pass through several hospital environments while a performance signal changes between sites.
Social good & healthEurope+2 clusters01

Explainable AI improved oncologists’ lung-cancer predictions, but external validation exposed the limits

A multi-country study in Nature Medicine evaluated explainable AI support for treatment decisions in advanced non-small-cell lung cancer. The retrospective I3LUNG cohort included 2,396 patients treated with immunotherapy-based regimens across six centers in six countries. Models using routine clinical and blood data achieved test performance up to an area under the curve of 0.77 and outperformed traditional single biomarkers and clinical scores in the independent test set. In a separate usability study, twenty oncologists reviewed one hundred cases first without and then with model predictions and SHAP-based explanations. Sensitivity for predicting disease control increased from 0.72 to 0.87, with gains in accuracy and F1 performance; overall-survival prediction improved more modestly. The paper is valuable because it reports the limits alongside the gains. External-validation performance fell to an AUC range of 0.55 to 0.72, the complete multimodal sample was small, and added imaging, pathology, and genomic data did not produce a reliable benefit across test and external cohorts. Differences between patient populations may explain some decline, which is exactly why local calibration and prospective evaluation matter. The authors describe silent prospective validation in more than two thousand patients, another usability study, and a planned pragmatic randomized trial before deployment. The result is promising decision support, not autonomous clinical authority.

7 min
An empty operating room with a transparent clinical checklist faces an illuminated semiconductor fabrication plant beyond glass.
Social good & healthSouth Korea / Global+3 clusters02

AI chips are minting profit. Surgical AI still has a much thinner evidence base

Two numbers in today's sources deserve to be held side by side without pretending they belong to the same transaction. Samsung's preliminary guidance puts third-quarter operating profit at 107.4 trillion won, nearly nine times the year-earlier figure, as demand and prices for AI-related memory support earnings. These are projected company results, with a detailed divisional breakdown due later; they do not measure the social value delivered by every AI application. Separately, a peer-reviewed scoping review in npj Digital Surgery searched five databases and identified 3,020 records on intraoperative AI clinical decision support. Only five studies met its specific inclusion criteria: one completed feasibility study and four ongoing prospective studies or registries. That does not mean only five AI-in-surgery studies exist, and it does not show these systems are unsafe. It means the prospective clinical and ethical evidence under this review's narrow question remains early. The contrast is about timing and incentives. Markets can reward the infrastructure that makes AI possible long before clinical systems have demonstrated safety, equity, consent and real patient benefit under routine conditions. A chip supplier is not responsible for conducting every surgical trial, and clinical validation properly takes longer than a quarterly earnings report. Still, the scale of investment creates a public expectation: buyers and hospitals should demand prospective outcomes and override procedures before live recommendations influence care. The impressive profit is real as a company forecast. The patient benefit is a separate question that must be tested.

7 min
Hundreds of luminous search threads converge on one repeating DNA pattern before it passes to a human scientist at a laboratory bench.
Social good & healthUnited States and global genomic data+4 clusters03

Claude agents found a previously uncharacterized enzyme system with CRISPR-like repeats

Anthropic says a campaign of roughly 950 Claude agents found a previously uncharacterized biological system while mining public DNA-sequence data. Over about 21 hours and 210 million tokens, the agents gathered more than 200,000 reverse transcriptases, selected roughly 3,500 candidate systems, and narrowed the field to about 20 detailed reports. One agent noticed evenly spaced non-coding DNA repeats beside an unusual reverse transcriptase and an accessory gene in bacteriophages. Anthropic calls the system array-associated reverse transcriptases, or ART. The arrangement resembles CRISPR arrays, and early experiments indicate that the ART array is expressed as distinct short RNAs. That does not establish a new gene-editing tool. Anthropic states that ART's natural function is unknown, the underlying reverse transcriptase had appeared in earlier studies, and all laboratory experiments were performed by human scientists. The work is a preprint from an Anthropic research group and its own Bay Area lab, so independent replication and peer review remain essential. The important signal is methodological. Agents can expand genome mining by running hundreds of searches and critiques in parallel, while expert judgment and physical experiments decide which machine-generated hypotheses survive. If replicated, the productivity gain may come less from replacing biologists than from making the neglected parts of enormous public datasets searchable at a new scale.

10 min
An ordinary chest CT reveals a small illuminated esophageal lesion while an AI triage path directs the patient toward confirmatory endoscopy.
Social good & healthChina and international validation sites+4 clusters04

AI found hidden esophageal cancers in CT scans patients already had

A multicenter Nature Medicine study reports that an AI system called EAGLE can identify esophageal cancer and precancerous lesions in noncontrast chest CT scans that were not acquired specifically for the esophagus. The model was trained on 6,813 patients and validated across 12 centers in three countries involving 80,612 patients. In external cohorts totaling 11,466 people, it reached 90.0 percent sensitivity for cancer and 98.5 percent specificity, while sensitivity for precancerous lesions was lower at 52.5 percent. A calibration cohort of 35,402 patients reduced false positives by 72.7 percent while preserving sensitivity. In a prospective hospital cohort of 17,446 patients, 38 of 90 positive predictions were true positives, producing a 42.2 percent positive predictive value and 87.8 percent sensitivity for cancer. A real-world low-dose screening cohort of 10,959 people reported 99.94 percent specificity. The opportunity is unusually practical: use scans already being performed to identify people who should receive confirmatory endoscopy. But the strongest efficiency claims remain modeled. Simulations suggested triage could triple detection, reduce diagnostic time by 70.4 percent, and lower costs in seven of eight countries. Those are not randomized outcomes or evidence of reduced mortality. Most data came from China, follow-up was under two years, endoscopy adherence was limited, and broader validation is needed for different disease patterns. EAGLE may make existing imaging more valuable. It has not yet proved that population deployment improves survival or avoids harmful overdiagnosis.

10 min
Thousands of AI agent nodes spiral into a fluid vortex beside a formal proof chain and an independent review stamp waiting to close.
Social good & healthGlobal+4 clusters05

OpenAI says 10,000 AI agents solved the Navier-Stokes problem

OpenAI says an internal system significantly more capable than GPT-6 Astra produced an analytical proof that smooth three-dimensional fluid motion can develop a singularity in finite time under a smooth external force. That would resolve the Navier-Stokes existence and smoothness Millennium Prize problem by establishing the counterexample formulations labeled C and D in the official statement. The company released a 166-page writeup and a Lean formalization, says the decisive effort involved roughly 10,000 concurrent agents, and reports that the Navier-Stokes work used about 2.7 million agent messages and 130 billion output tokens. It does not intend to claim the million-dollar prize. The result is potentially historic, but the correct verb today is claims, not solved. A formal proof artifact makes checking more rigorous and transparent, yet experts must still verify that the definitions, assumptions, and formal statements match the intended problem and that no gap sits outside the encoded proof. Provenance also matters. OpenAI says it began after hearing rumors about related work, did not access the outside researchers' specific user data, and cannot entirely rule out indirect influence from de-identified data used to improve models. The episode therefore demonstrates both the promise and the governance burden of AI-accelerated science. Massive parallel search can attack problems at a scale unavailable to most mathematicians. Scientific legitimacy will depend on independent verification, reproducible artifacts, careful credit, and clear policies protecting unpublished work submitted to commercial AI systems.

6 min
Six protein biomarker dials converge on an experimental molecule above a lung scan while an unfinished trial path continues into shadow.
Social good & healthGlobal+2 clusters06

An AI-discovered lung drug shifted six aging clocks, not human lifespan

An experimental drug developed with AI has produced a result that is scientifically interesting and extremely easy to oversell. Rentosertib was designed for idiopathic pulmonary fibrosis, a progressive scarring disease of the lungs. Its target was identified with AI and its molecule was generated through an AI-driven discovery platform. Researchers analyzed protein data from 42 patients in a 12-week phase 2a trial and applied six independently developed proteomic aging clocks. All six estimated a reduction in predicted biological age among treated patients. Earlier trial results also showed a promising dose-related improvement in forced vital capacity, an important lung-function measure. Agreement across multiple clocks makes the signal less likely to be an artifact of one aging model. It does not prove that the drug extends life, reverses aging throughout the body, or is safe and effective as a longevity treatment. The cohort was small, the follow-up was short, the participants had a serious age-related disease, and improving inflammation or fibrosis can change proteins used by aging clocks. The Nature Biotechnology paper also discloses that several authors work for the company developing the drug and that its company leader is an author. The responsible interpretation is neither miracle nor dismissal. This is a hypothesis-generating biomarker result attached to a candidate that has advanced in clinical development. Larger, longer, independently scrutinized trials should prespecify aging endpoints and connect them with functional outcomes, safety, disease progression, and eventually survival. AI accelerated the discovery path. Biology still decides whether the claim survives.

5 min
An uncertainty-aware AI map narrows hundreds of possible chemistry experiments to one illuminated vial while a laboratory counter records fewer physical trials.
Social good & healthGlobal+2 clusters07

A language model learned uncertainty and reached results with 41 percent fewer experiments

A Nature Machine Intelligence study introduces GOLLuM, a framework that trains language models through the probabilistic objective used in Gaussian-process Bayesian optimization. Instead of treating a language model as a confident generator of experimental suggestions, the method reshapes its internal representation using observed outcomes and calibrated uncertainty so it can help decide which experiment to run next. Starting from ten low-performing experiments, GOLLuM ranked first on average across 23 tasks spanning organic synthesis, process chemistry, materials, catalysis, and molecular design. It matched traditional Bayesian optimization's final performance with a median 41 percent fewer iterations. In a Buchwald–Hartwig reaction benchmark, the approach nearly doubled the discovery rate for high-performing conditions compared with expert quantum-chemical descriptors and state-of-the-art language models, 43 percent versus 24 to 25 percent. The result matters because laboratory time, materials, and failed experiments are expensive. It also shows that uncertainty can be part of a model's training objective rather than a confidence label added afterward. The evidence comes from benchmarked experimental-design tasks, not unrestricted autonomous laboratories. Domain review, physical safety limits, dataset quality, secondary objectives, replication, and transparent decision records remain necessary before an optimization gain becomes a discovery system people can trust.

6 min
A conventional microscope with a compact motorized stage scans a bone-marrow slide and routes candidate-cell evidence to a gloved clinical reviewer.
Social good & healthUnited States and Global+3 clusters08

A low-cost self-driving microscope screens bone marrow slides for acute leukemia

A Nature Communications study presents ALLocate, a low-cost AI-powered plugin that turns a conventional microscope into a self-driving screening system for acute leukemia. The system automatically selects useful bone-marrow regions, detects cells, and produces a slide-level result without a whole-slide scanner. Researchers trained and evaluated it with more than 11,000 annotated regions and 130,000 annotated cells, then used independent multi-institutional cohorts that included 165 physical bone-marrow smear slides. Reported performance exceeded 0.99 AUROC for region selection, reached 0.90 mean average precision for cell detection, and achieved 88 percent accuracy for diagnosis on glass slides. That combination could make automated screening more accessible where scanners and specialist expertise are scarce. It does not support an autonomous final diagnosis. An 88 percent result leaves clinically important errors, and the study does not erase the need for population-specific validation, slide-quality checks, calibration, human confirmation, and escalation to a pathologist. The strongest deployment is a lower-cost bridge to expertise, not a substitute for it.

5 min
A patient and clinician face a polished medical AI prism while trust and safety evidence remain obscured behind a frosted clinical wall.
Social good & healthGlobal+3 clusters09

Medical AI studies measure satisfaction far more than trust or safety

A Nature Health systematic review of 330 medical-AI studies found that patient factors are rarely integrated across the full AI lifecycle and are heavily concentrated in late validation. Among the papers reviewed, 70.6 percent assessed patient satisfaction and 69.4 percent perceived benefits, but only 16.7 percent examined trust and 10.9 percent safety. Patient factors were assessed during validation in 89.4 percent of cases, while only 3.9 percent incorporated them during design and development. The analysis covers reported studies rather than new patient-level data, and the included research spans different applications and methods, so the percentages should not be treated as a single performance score for medical AI. The pattern is still consequential. A patient can report a satisfying interaction without understanding the system, trusting the institution that uses it, or being protected from error and harm. If trust, safety, usability, adherence, privacy, and patient characteristics arrive only after a model is built, the product may optimize for a population and workflow that never existed outside the laboratory.

5 min
A wall of 1,357 medical-device approval tiles narrows to three illuminated patient-outcome records beside an empty hospital evidence chart.
Social good & healthUnited States · Global implications+3 clusters10

Only three of 1,357 FDA-authorized AI medical devices were evaluated on patient outcomes

A PLOS Digital Health evidence census linked the FDA's 1,357 authorized AI and machine-learning medical devices through December 5, 2025 to prospective trials and publications. Thirty-four devices were linked to registered prospective trials, 12 had posted results, 12 had peer-reviewed publications, and only three evaluated patient-centered outcomes such as mortality, morbidity, or readmission. The review does not show that the remaining devices are ineffective; it shows that authorization and benchmark performance rarely answer the outcome question patients care about most. With 78 percent of the devices concentrated in radiology and vulnerable populations often excluded from studies, the validation gap can travel through hospitals and across countries long before durable benefit or equitable performance is known.

5 min
Several luminous designed protein binders attach to a transparent molecular target above a physical laboratory assay tray.
Social good & healthGlobal+4 clusters11

Claude designs protein binders that survive wet-lab testing

Anthropic reports that Claude Opus 4.8 and Mythos Preview designed protein binders against 15 targets and succeeded against 14 after external laboratories produced and tested the designs. Reported hit rates ranged from 22.6 percent to 35.1 percent depending on the setup, above the 10 to 15 percent that Anthropic says is typical in current campaigns. The models orchestrated existing protein-design and folding tools with minimal human scientific guidance, producing 354 confirmed binders from 1,320 designs. This is a meaningful result because physical testing separates a scientific claim from a plausible-looking output. It is not a finished drug. Minibinders are an early design step, one target failed, additional characterization is planned, and the campaigns used substantial compute and specialist infrastructure. The same autonomy is dual-use, so Anthropic says its strongest biological capabilities remain restricted while it develops scientist access. The breakthrough and the control problem arrive together.

7 min
A strand of artificial intelligence code becomes a bacteriophage above a laboratory petri dish, marking the transition from digital design to living replication.
Social good & healthUnited States+4 clusters12

Scientists used AI to design viable viruses. The safety boundary just crossed into biology

Scientists used genome language models to design 16 viable bacteriophages that infected and killed the bacterium E coli in laboratory tests. The New York Times reports the peer-reviewed publication of work in which researchers generated thousands of candidate genomes, synthesized 285 designs, and identified 16 functional phages. These are viruses that target bacteria, not humans; Arc Institute says the models excluded eukaryotic viruses from training and the working phages showed restricted host range in testing. The result is both a therapeutic opportunity and a dual-use warning. AI-assisted phage design could help attack antibiotic-resistant bacteria, but it also proves that generative output can become a replicating biological system once synthesis and experimentation enter the chain.

5 min
A human speech bubble and an AI speech bubble converging around a heart-shaped support signal with an actionable-steps checklist.
Social good & healthUnited Kingdom+4 clusters13

AI chatbots matched human emotional support in everyday situations

Five studies involving 1,233 participants compared responses from ChatGPT 4o, Claude 3.5 Sonnet, Gemini 1.5 Pro, and human participants across everyday, non-clinical emotional situations. The AI responses were rated as more supportive for anger and fear, performed about as well as people for sadness, and still helped when recipients correctly suspected they came from a machine. The strongest factor was not generic validation but specific, actionable guidance.

3 min
A federal AI and supercomputing hub connecting health data, drug discovery, infrastructure materials, and scientific research.
Social good & healthUnited States+3 clusters14

A $5 billion federal push links AI to health, infrastructure and science

The U.S. government has committed more than $5 billion to expand the Genesis Mission, a multi-agency effort that combines federal datasets, Department of Energy supercomputers, research facilities, and AI tools. More than 15 agencies and 278 selected projects will target problems including chronic disease, pediatric cancer, drug discovery, resilient building materials, transportation maintenance, energy, manufacturing, agriculture, and national security.

3 min
A wearable bioelectronic patch linking biosensing, an AI decision node, human oversight, and controlled therapy in a closed loop.
Social good & healthGlobal+2 clusters15

Gao et al., “AI-powered closed-loop wearable bioelectronics for personalized and autonomous healthcare”

A Nature Sensors review argues that AI-powered closed-loop wearables could move healthcare devices beyond passive data collection by connecting continuous biosensing directly to AI-guided decisions and therapeutic intervention. The authors emphasize that clinical value depends on the coordinated system—sensing, control, treatment, and human oversight—not any component alone. Long-term interface stability, robust control, transparent safety mechanisms, and evidence of patient benefit remain prerequisites for scalable use.

3 min
A warped molecular structure resolving into a physically constrained chemical lattice.
Work & marketsGlobal+3 clusters16

Liu et al., “Integrating chemical priors and physical laws to mitigate hallucinations in structure-based drug design”

The NUS/Harbin-led team identifies a domain-specific form of generative-AI hallucination: molecular candidates can receive strong predicted binding scores while violating basic chemistry or producing physically impossible atomic arrangements. Its DrugRPG framework incorporates chemical-foundation-model priors and differentiable physical constraints during molecule generation, reducing severe steric clashes by 65.4% relative to the reported state-of-the-art baseline and increasing by 28.6% the share of generated candidates meeting combined potency, stability, and synthetic-feasibility criteria.

2 min
A clinical waveform and reinforcement-learning decision tree ending at an evidence gap.
Cognition & learningGlobal+2 clusters17

Tang et al., “Reinforcement learning for treatment decision-making in sepsis: a scoping review”

Reviewing 72 studies of reinforcement-learning systems for sepsis treatment, the authors found that every study was retrospective, 58 studies—80.6%—relied on the same MIMIC critical-care database, and only 10 used private datasets. Although many papers claimed that AI-derived treatment policies outperformed clinicians, variation in how patient states, treatment actions, rewards, and counterfactual outcomes were defined made those comparisons difficult to validate.

2 min
Cognition & learningGlobal+2 clusters18

Souei et al., “Artificial intelligence in deep brain stimulation for movement disorders: a systematic review and technology readiness assessment”

Researchers reviewed 239 peer-reviewed studies on AI-supported deep-brain stimulation and found a pronounced gap between reported algorithmic performance and clinical readiness. External validation remained rare, evaluations were predominantly retrospective and single-centre, and more than one-quarter of studies used small, high-dimensional datasets with elevated overfitting risk; most systems therefore remained at early-to-intermediate technology-readiness levels.

2 min
Technical failuresGlobal+2 clusters19

Shen et al., “Generalizable AI predicts immunotherapy outcomes across cancers and treatments”

A Harvard/Broad/MIT-linked team introduced COMPASS, a pan-cancer foundation model that predicts immune-checkpoint-inhibitor response from tumor transcriptomes and interpretable immune concepts. The model was trained on 10,184 tumors across 33 cancer types and reportedly outperformed 22 existing approaches across 16 clinical cohorts covering seven cancers and six immunotherapy agents, with predicted responders showing longer overall survival.

2 min